Hyd-based Biophore seeks DCGI approval for the use of Aviptadil in COVID treatment – Deccan News

Hyderabad: Biophore India Pharmaceuticals, based in Hyderabad, announced on Friday that they are applying for approval by DCGI for emergency use of Aviptadil Inhalation for marketing in India for the treatment of moderate to severe cases of Covid-19.

Biophore successfully developed Aviptadil and was subsequently integrated into the internal API (Active Pharmaceutical Ingredient).

The company starts commercial production immediately after receiving the approval of the Drug Control General of India (DCGI).

Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) which, when administered, leads to rapid clinical recovery in patients with severe SARS-COV-2 infection.

These observations are based on the results of multiple trials with Aviptadil against Covid-19 worldwide in patients with respiratory failure and the same has been submitted to DCGI for their review, it is said.

Biophore developed this very complex peptide in a very short period of time, mainly due to the company’s extensive focus on Covid related products during the past year.

Aviptadil is a very promising treatment option for Covid, especially in serious cases admitted to hospital, where trials have shown a high recovery rate and we hope we can make it available quickly through this approval, “said Biophore CEO Jagadeesh Babu Rangisetty.

Biophore was actively involved in the development of products against Covid-19 and scaling up manufacturing to meet the requirements. The company was one of the first few manufacturers to get approval for an antiviral drug, Favipiravir, in India during the first wave and is also the only Indian manufacturer to produce multivolume Sulfobutyl Ether beta-cyclodextrin (SBECD). which is an important tool in the manufacture of Remdesivir injections.

Apart from this, Biophore has invested significantly in the research and development of other anti-Covid products during the past year

“While we are optimistic that the pandemic will end soon, we need to be prepared for emergencies. We need to continue to evaluate and add new products against this virus to ensure better preparedness by having more options for the treating physicians and thus avoiding shortages. Our goal is also to make the cost of treatment affordable, especially for patients admitted to the hospital, ”said Jagadeesh Babu.

Source: The Siasat Daily

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button